ClinicalTrials.gg
CompletedNCT05476900Updated Mar 24, 2025

A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.

A Phase 2 interventional study of HR19042 Capsules in Autoimmune Hepatitis, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Hepatitis, Autoimmune with a site in China — 3 open to participants now, 3 under way, 1 of them phase 3. Hepatitis, Autoimmune · China.

Enrollment
6th of 10
69 · median 74
Started
2022
with 1 other
Phase 2
Only one
of the 16
Registered
10th of 16
by date
Lead sponsor
2 of 16
Jiangsu HengRui Medicine Co., Ltd.

Among the 16 studies in Hepatitis, Autoimmune with a site in China, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 2, and was the 10th registered.

Hepatitis, Autoimmune

82 studies on the registry are indexed under Hepatitis, Autoimmune; 24 are open to participants now.

Browse Hepatitis, Autoimmune studies →

Open to participants now

3 of the 16 studies in Hepatitis, Autoimmune with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 16 Hepatitis, Autoimmune studies recruiting now, 9 (56%) set no upper age limit and 4 (25%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hepatitis, Autoimmune with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042 capsules administration for the treatment.

03

Conditions studied

  • Autoimmune Hepatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old≤Female or male patients≤70 years old;
  2. Clinical-confirmed hepatitis;
  3. -confirmed autoimmune hepatitis;
  4. Serum (ALT) or aspartate aminotransferase (AST) level ≥ 3 × (ULN);
  5. Willing and able to give and follow the protocols during the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other chronic liver diseases;
  2. Patients with liver cirrhosis;
  3. Patients with hepatic encephalopathy;
  4. Positive results in -Ab/TP-Ab/hepatitis virus tests
  5. Severe chronic or active infection requiring systemic anti-infective therapy within 14 days before screening;
  6. Patients with severe cardiovascular diseases;
  7. Patients with within the past 5 years;
  8. Patients received organ transplantation;
  9. Patients treated with any systemic within 3 months before screening;
  10. Patients treated with any systemic drugs within the 6 months before screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    12 mg HR19042 Capsules QD

    Drug: HR19042 Capsules

  • Experimental
    4 mg HR19042 Capsules TID

    Drug: HR19042 Capsules

  • Experimental
    8 mg HR19042 Capsules QD

    Drug: HR19042 Capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of biochemical response after 12 weeks of treatment.

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of biochemical response with the absence of glucocorticoid-related adverse events after 12 weeks of treatment.

    Time frame: 12 weeks

  2. Percentage of partial response after 12 weeks of treatment

    Time frame: 12 weeks

  3. Percentage of biochemical response after 24 weeks of treatment.

    Time frame: 24 weeks

  4. Percentage of biochemical response with the absence of glucocorticoid-related adverse events after 24 weeks of treatment.

    Time frame: 24 weeks

  5. Percentage of partial response after 24 weeks of treatment.

    Time frame: 24 weeks

  6. Change from baseline in serum ALT levels.

    Time frame: 2, 4, 8, 12, 18, 24 weeks

  7. Change from baseline in serum AST levels.

    Time frame: 2, 4, 8, 12, 18, 24 weeks

07

Study locations

1 site
  • Shanghai Jiao Tong University School of Medicine, Renji Hospital
    Shanghai, Shanghai 200120, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Mar 2025, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Jul 27, 2022
StartActual
Oct 6, 2022
Primary completionActual
Mar 14, 2025
CompletionActual
Mar 14, 2025
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05476900
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
Oct 6, 2022
Primary completion
Mar 14, 2025
Completion
Mar 14, 2025
Last update
Mar 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HR19042

Start the discussion